LONDON--GlaxoSmithKline PLC (GSK.LN) Monday said it has started a second phase study to evaluate the efficacy and safety of an antibody in patients with inflammatory hand osteoarthritis.

The healthcare company said the main objective of the randomized, placebo-controlled and parallel-group study is to assess the efficacy potential of subcutaneous injections of the antibody on pain. The secondary objectives is to assess the safety and pharmacokinetics of the antibody, the company said.

Shares at 0950 GMT up 2.50 pence, or 0.2%, at 1,508.50 pence valuing the company at 73.5 billion pounds ($104.66 billion).

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

April 18, 2016 06:06 ET (10:06 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.